Wilderness & Environmental Medicine
Volume 21, Issue 2 , Pages 146-155 , June 2010

Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness

  • Andrew M. Luks, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA
    • Corresponding Author InformationCorresponding author: Andrew Luks, MD, Assistant Professor, Pulmonary and Critical Care Medicine, Harborview Medical Center, 325 Ninth Ave, Box 359762, Seattle, WA 98104
    • ,
  • Scott E. McIntosh, MD, MPH

      Affiliations

    • Division of Emergency Medicine, University of Utah, Salt Lake City, UT
    • ,
  • Colin K. Grissom, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center and the University of Utah, Salt Lake City, UT
    • ,
  • Paul S. Auerbach, MD, MS

      Affiliations

    • Department of Surgery, Division of Emergency Medicine, Stanford University School of Medicine, Palo Alto, CA
    • ,
  • George W. Rodway, PhD, APRN

      Affiliations

    • College of Nursing and School of Medicine, University of Utah, Salt Lake City, UT
    • ,
  • Robert B. Schoene, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA
    • Bozeman Deaconess Hospital, Bozeman, MT
    • ,
  • Ken Zafren, MD

      Affiliations

    • Department of Surgery, Division of Emergency Medicine, Stanford University School of Medicine, Palo Alto, CA
    • Himalayan Rescue Association, Kathmandu, Nepal
    • ,
  • Peter H. Hackett, MD

      Affiliations

    • Division of Emergency Medicine, Altitude Research Center, University of Colorado Denver School of Medicine, Denver, CO
    • Institute for Altitude Medicine, Telluride, CO

References 

  1. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129:174–181
  2. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345:107–114
  3. Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol. 2004;5:136–146
  4. Schoene RB. Illnesses at high altitude. Chest. 2008;134:402–416
  5. Bloch KE, Turk AJ, Maggiorini M, et al. Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 m. High Alt Med Biol. 2009;10:25–32
  6. Beidleman BA, Fulco CS, Muza SR, et al. Effect of six days of staging on physiologic adjustments and acute mountain sickness during ascent to 4300 meters. High Alt Med Biol. 2009;10:253–260
  7. Hackett PH, Rennie D. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976;2:1149–1155
  8. Forwand SA, Landowne M, Follansbee JN, Hansen JE. Effect of acetazolamide on acute mountain sickness. N Engl J Med. 1968;279:839–845
  9. Basnyat B, Gertsch JH, Holck PS, et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the Prophylactic Acetazolamide Dosage Comparison for Efficacy (PACE) trial. High Alt Med Biol. 2006;7:17–27
  10. van Patot MC, Leadbetter G, Keyes LE, Maakestad KM, Olson S, Hackett PH. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol. 2008;9:289–293
  11. Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol. 2001;2:389–403
  12. Ellsworth AJ, Larson EB, Strickland D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med. 1987;83:1024–1030
  13. Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med. 1991;154:289–293
  14. Roncin JP, Schwartz F, D'Arbigny P. EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med. 1996;67:445–452
  15. Moraga FA, Flores A, Serra J, Esnaola C, Barriento C. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness Environ Med. 2007;18:251–257
  16. Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165:296–301
  17. Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the Prevention of High Altitude Illness Trial (PHAIT). BMJ. 2004;328:797
  18. Leadbetter G, Keyes LE, Maakestad KM, Olson S, Tissot van Patot MC, Hackett PH. Ginkgo biloba does—and does not—prevent acute mountain sickness. Wilderness Environ Med. 2009;20:66–71
  19. Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest. 2008;133:744–755
  20. Bartsch P, Merki B, Hofstetter D, Maggiorini M, Kayser B, Oelz O. Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ. 1993;306:1098–1101
  21. Keller HR, Maggiorini M, Bartsch P, Oelz O. Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial. BMJ. 1995;310:1232–1235
  22. Taber RL. Protocols for the use of portable hyperbaric chambers for the treatment of high altitude disorders. J Wild Med. 1990;1:181–192
  23. Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med. 1992;116:461–465
  24. Ferrazzini G, Maggiorini M, Kriemler S, Bartsch P, Oelz O. Successful treatment of acute mountain sickness with dexamethasone. Br Med J (Clin Res Ed). 1987;294:1380–1382
  25. Hackett PH, Roach RC, Wood RA, et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med. 1988;59:950–954
  26. Levine BD, Yoshimura K, Kobayashi T, Fukushima M, Shibamoto T, Ueda G. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med. 1989;321:1707–1713
  27. Stream JO, Grissom CK. Update on high-altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness Environ Med. 2008;19:293–303
  28. Bartsch P, Mairbaurl H, Maggiorini M, Swenson ER. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol. 2005;98:1101–1110
  29. Bartsch P, Maggiorini M, Mairbaurl H, Vock P, Swenson ER. Pulmonary extravascular fluid accumulation in climbers. Lancet. 2002;360:571
  30. Singh I, Kapila CC, Khanna PK, Nanda RB, Rao BD. High-altitude pulmonary oedema. Lancet. 1965;191:229–234
  31. Bartsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med. 1991;325:1284–1289
  32. Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med. 2002;346:1631–1636
  33. Maggiorini MBrunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med. 2006;145:497–506
  34. Hohne C, Krebs MO, Seiferheld M, Boemke W, Kaczmarczyk G, Swenson ER. Acetazolamide prevents hypoxic pulmonary vasoconstriction in conscious dogs. J Appl Physiol. 2004;97:515–521
  35. Shimoda LA, Luke T, Sylvester JT, Shih HW, Jain A, Swenson ER. Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition. Am J Physiol Lung Cell Mol Physiol. 2007;1013–1022
  36. Teppema LJ, Balanos GM, Steinback CD, et al. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia. Am J Respir Crit Care Med. 2007;175:277–281
  37. Basnyat B, Hargrove J, Holck PS, et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol. 2008;9:209–216
  38. Marticorena E, Hultgren HN. Evaluation of therapeutic methods in high altitude pulmonary edema. Am J Cardiol. 1979;43:307–312
  39. Zafren K, Reeves JT, Schoene R. Treatment of high-altitude pulmonary edema by bed rest and supplemental oxygen. Wilderness Environ Med. 1996;7:127–132
  40. Freeman K, Shalit M, Stroh G. Use of the Gamow Bag by EMT-basic park rangers for treatment of high-altitude pulmonary edema and high-altitude cerebral edema. Wilderness Environ Med. 2004;15:198–201
  41. Oelz O, Maggiorini M, Ritter M, et al. Nifedipine for high altitude pulmonary oedema. Lancet. 1989;2:1241–1244
  42. Fagenholz PJ, Gutman JA, Murray AF, Harris NS. Treatment of high altitude pulmonary edema at 4240 m in Nepal. High Alt Med Biol. 2007;8:139–146
  43. Schoene RB, Roach RC, Hackett PH, Harrison G, Mills WJ. High altitude pulmonary edema and exercise at 4,400 meters on Mount McKinley (Effect of expiratory positive airway pressure). Chest. 1985;87:330–333

PII: S1080-6032(10)00114-6

doi: 10.1016/j.wem.2010.03.002

Wilderness & Environmental Medicine
Volume 21, Issue 2 , Pages 146-155 , June 2010

Article Tools